<DOC>
	<DOCNO>NCT00503698</DOCNO>
	<brief_summary>This trial conduct Africa , Asia , Europe , North South America Oceania . The aim trial evaluate effect somatropin ( human growth hormone ) survival ( primary end-point ; `` time death '' health relate quality life adult patient chronic haemodialysis .</brief_summary>
	<brief_title>The Effect Somatropin Treatment Adult Patients Chronic Dialysis</brief_title>
	<detailed_description>The decision discontinue trial due safety concern . The discontinuation base analysis significant delay recruitment patient expect negative impact outcome trial .</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<criteria>Serum albumin specify protocol Malnourished ( base serum albumin value 40 g/L , assess centrally ) Stable ( 3 month ) adequate haemodialysis treatment three month prior enrolment define Kt/V 1.2 Active malignant disease Critical illness require treatment intensive care unit ( ICU ) Uncontrolled treated/untreated hypertension Patients chronic ( 3 month ) treatment steroid dose 10 mg/day prednisolone ( equivalent ) Patients treated immunosuppressive agent Known Growth Hormone Deficiency Patients suffer clinically significant disease history opinion investigator Severe illness define protocol ( judged investigator )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>